Literature DB >> 2199129

Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I).

R Zini1, P Riant, J Barré, J P Tillement.   

Abstract

Many diseases appear to lead to a decrease of drug plasma binding due either to hypoalbuminaemia or to a modification of albumin structure. In other diseases, the binding of a drug may increase due to elevated concentrations of alpha 1-acid glycoprotein or lipoproteins. However that may be, the free fraction of a drug may vary in different pathologies. But an increase or decrease of the drug free fraction does not automatically mean an increase or decrease of the free drug concentration. Whatever the drug, a variation in the volume of distribution more or less proportional to the variation in the plasma free fraction can be expected. With respect to the clearance, the problem is much more complex and depends on the hepatic extraction ratio of drug. If the extraction is related to the free fraction (fu) of drug, a variation in fu will lead to a variation in the total drug concentration but no variation in the free drug concentration and no change in the pharmacological effect. If the extraction of a drug is dependent on hepatic flow, a variation in fu will lead to a change in the free drug concentration (with no change in the total drug concentration) and hence changes in the pharmacological effect. The aim of this article is to review the literature concerning disease-induced variations in plasma protein levels during the past 10 years. Finally, possible implications for drug dosage regimens are discussed generally from examples studies in the literature.

Mesh:

Substances:

Year:  1990        PMID: 2199129     DOI: 10.2165/00003088-199019020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  23 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 2.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

3.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 4.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 5.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

6.  Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

Authors:  Shripad D Chitnis; Ken Ogasawara; Björn Schniedewind; Reginald Y Gohh; Uwe Christians; Fatemeh Akhlaghi
Journal:  Xenobiotica       Date:  2013-01-02       Impact factor: 1.908

7.  Lack of accumulation of midazolam in plasma and lipoprotein fractions during intravenous lipid infusions in patients on artificial respiration.

Authors:  I Walter-Sack; J X de Vries; J Rudi; R Conradi; M Kohlmeier; B Kohl; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Cefpiramide kinetics and plasma protein binding in cholestasis.

Authors:  F Demontes-Mainard; G Vinçon; L Labat; M Amouretti; J Necciari; G Kieffer; B Bannwarth
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

9.  Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites.

Authors:  A J McLachlan; D J Cutler; S E Tett
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.

Authors:  Khalid M Alkharfy
Journal:  Exp Diabetes Res       Date:  2009-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.